Filter Results:
(924)
Show Results For
- All HBS Web
(924)
- People (2)
- News (70)
- Research (773)
- Events (1)
- Multimedia (2)
- Faculty Publications (664)
Show Results For
- All HBS Web
(924)
- People (2)
- News (70)
- Research (773)
- Events (1)
- Multimedia (2)
- Faculty Publications (664)
Roberto Verganti
Roberto Verganti is in the Technology and Operations Management Unit at Harvard Business School. He teaches Design Theory and Practice for the double degree program MS/MBA conducted jointly by the Harvard Business School and the... View Details
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Testing and Trials; Health Care and Treatment; Business Model; Problems and Challenges; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
- 20 Nov 2007
- First Look
First Look: November 20, 2007
discipline to nationalized banks. Pharmaceutical Regulation in the United States and Europe Author:Arthur Daemmrich Periodical:Focus on Law Studies 23, no 1 (fall 2007): 8-11 Read the full paper:... View Details
Keywords: Martha Lagace
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Production; Business Strategy; Pharmaceutical Industry
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
- May 2023 (Revised June 2023)
- Case
Novartis (A): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Leadership; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (A): Reimagining Medicine." Harvard Business School Case 723-443, May 2023. (Revised June 2023.)
Max H. Bazerman
Max H. Bazerman is Jesse Isidor Straus Professor of Business Administration at the Harvard Business School. His recent books... View Details
- 2010
- Working Paper
Accelerating Energy Innovation: Insights from Multiple Sectors
By: Rebecca Henderson and Richard G. Newell
A combination of concerns about climate change and energy security has recently led to significant increases in public funding for energy R&D. Some commentators are suggesting that these increases need to be sustained, and are advocating for increases of as much as... View Details
Keywords: Innovation and Management; Technological Innovation; Knowledge Use and Leverage; Research and Development; Pollutants; Climate Change; Energy Industry
Henderson, Rebecca, and Richard G. Newell. "Accelerating Energy Innovation: Insights from Multiple Sectors." Harvard Business School Working Paper, No. 10-067, February 2010. (Revised February 2011.)
Srikant M. Datar
Srikant M. Datar became the eleventh dean of Harvard Business School on 1 January 2021. During his tenure as a faculty member, he served as Senior Associate Dean for University Affairs (including Faculty Chair of the Harvard Innovation Lab), for Research, for... View Details
Keywords: accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry
- 02 Aug 2011
- First Look
First Look: August 2
pharmaceutical and skin care company. During World War I the expropriation of its brands and trademarks revealed its vulnerability to political risk. Following the advent of the Nazi regime in 1933, the largely Jewish owned and managed... View Details
Keywords: Sean Silverthorne
- 28 Mar 2023
- Research & Ideas
The FDA’s Speedy Drug Approvals Are Safe: A Win-Win for Patients and Pharma Innovation
Wiener Professor of Public Policy and Director of Health Policy Research at the Harvard Kennedy School of Government. Jennifer Kao of the University of California, Los Angeles and the FDA’s Kathleen Miller are also coauthors. Speeding innovation without compromising... View Details
- Web
Named Fellowship Funds - Alumni
Lowell and was a scientist in the aerospace industry prior to attending HBS. Following a career as a pharmaceutical executive and management consultant, she founded Circle of Life Partners, a network of... View Details
Ranjay Gulati
Ranjay Gulati is the Paul R. Lawrence MBA Class of 1942 Professor of Business Administration and the former Unit Head of the Organizational Behavior Unit at Harvard Business School. He is an expert on leadership, strategy, and organizational issues... View Details
- January 2009
- Case
When Supply is of Public Interest: Roche & Tamiflu
The case focuses on the challenges of Roche maintaining a supply network for a global influenza pandemic response initiative based on its antiviral drug Tamiflu. The Roche group is a 40 billion CHF company consisting of a pharmaceutical division and a diagnostic... View Details
Keywords: Global Strategy; Health Pandemics; Distribution; Logistics; Production; Supply Chain Management; Performance Capacity; Pharmaceutical Industry
Watson, Noel H., Laura Rock Kopczak, and Prashant Yadav. "When Supply is of Public Interest: Roche & Tamiflu." Harvard Business School Case 609-061, January 2009.
- 18 Apr 2023
- Research & Ideas
The Best Person to Lead Your Company Doesn't Work There—Yet
within their own ranks. “What you really do need is knowledge of that specific industry, whether it's pharmaceutical or manufacturing or hospitality or rocket science.” The findings suggest an active market for CEOs, who are lured to... View Details
Paul A. Gompers
Paul Gompers, Professor of Business Administration at the Harvard Business School, specializes in research on financial issues related to start-up, high growth, and newly public companies. Professor Gompers has an appointment in both the View Details
Joshua D. Margolis
Joshua Margolis is James Dinan and Elizabeth Miller Professor of Business Administration and the Unit Head for the Organizational Behavior unit. He is also Faculty Chair of the Program for Leadership Development. His research and teaching revolve around leadership... View Details
- 21 Feb 2018
- Research & Ideas
When a Competitor Abandons the Market, Should You Advance or Retreat?
Terminations: Learning from Competitors’ R&D Failures, Krieger explores how pharmaceutical companies choose to react strategically when a competitor exits the market during the development stage. These companies may decide further... View Details
- 2016
- Book
Consumers, Corporations, and Public Health: A Case-Based Approach to Sustainable Business
By: John A. Quelch
The public health footprint associated with corporate behavior has come under increased scrutiny in the last decade, with an increased expectation that private profit not come at the expense of consumer welfare.
Consumers, Corporations, and Public... View Details
Consumers, Corporations, and Public... View Details
Keywords: Consumer; Corporate Culture; Public Health; Consumer Behavior; Marketing Strategy; Corporate Strategy; Health; Innovation and Invention; Innovation and Management; Supply Chain Management; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Advertising Industry; Asia; Oceania; North and Central America; Middle East; Latin America; Europe
Quelch, John A. Consumers, Corporations, and Public Health: A Case-Based Approach to Sustainable Business. New York: Oxford University Press, 2016.
Nitin Nohria
Nitin Nohria served as the tenth dean of Harvard Business School from 2010-2020. He previously served as co-chair of the Leadership Initiative, Senior Associate Dean of Faculty Development, and Head of the Organizational Behavior unit.
As Dean, building on... View Details
Keywords: accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry
Malcolm P. Baker
Malcolm Baker is the Robert G. Kirby Professor of Business Administration at the Harvard Business School, where he teaches the required course in finance and a short immersive program on investing in life sciences.
His research is in the... View Details